Pseudoprogression in Lung Cancer after Immunotherapy Treatment

December 3, 2013
Naiyer A. Rizvi, MD

Naiyer A. Rizvi, MD, discusses the phenomenon of pseudoprogression in patients with lung cancer after they receive immunotherapy treatment.

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses the phenomenon of pseudoprogression in patients with lung cancer after they receive immunotherapy treatment.

Clinical Pearls:

  • Early scans that appear to be tumor growth may actually be delayed benefit of the treatment or inflammation of the tumor as T cells become active
  • This phenomenon occurs in less than 10% of patients
  • Physicians should consider the patient’s well being in addition to scans in order to make a decision